Idenix: Hepatitis C Treatment Effective
Monday January 10, 3:08 pm ET
Idenix Says Valopicitabine Hepatitis C Treatment Shown Effective in Clinical Trials
SAN FRANCISCO, Calif. (AP) -- Biopharmaceutical company Idenix Pharmaceuticals Inc. reported Monday that its hepatitis C treatment, valopicitabine plus pegylated interferon, reduced levels of the virus by 99.94 percent in clinical trials.
[Non-text portions of this message have been removed]